Annuaire
Personnel hébergé
M. Denis Mulleman
Main duties and past experience in my research Research unit: - Coordinator of the Consortium «Monitoring of monoclonal Antibodies Group in Europe» (MAGE) for inflammatory diseases (Mai 2015-December 2017). The MAGE Consortium is supported by LE STUDIUM Loire Valley Institute for Advanced Studies (http://www.lestudium-ias.com/). - Representative in the ABIRISK consortium (www.abirisk.eu) dedicated to immunogenicity to biopharmaceutical March 2012-March 2018. - co-leader of the key question N°3 of the Laboratory of Excellence MabImprove (“How can antibodies efficacy can be increased using combination) with Laurent Gros (Inserm (http://mabimprove.univ-tours.fr/en/) (December 2017-present). - Guest researcher at the University of Uppsala (Siv Jönsson and Mats Karlsson) at the department of pharmacometrics (sept 2019-August 2020) - Chair of the COST Action CA21147 ENOTTA European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases (November 2022-November 2026) https://enotta.eu/Coordonnées
- Tél
- 0247366368
- denis.mulleman@univ-tours.fr
- Site internet
- http://cbm.cnrs-orleans.fr/en/le-laboratoire-accueil/
Discipline(s)
Rhumatologie
Thèmes de recherche
Key words:
Biopharmaceuticals, Advanced therapy medicinal product, monoclonal antibodies, cellular response, therapeutic drug monitoring, immunogenicity, quantitative systems pharmacology, inflammatory rheumatic diseases
Biopharmaceuticals, Advanced therapy medicinal product, monoclonal antibodies, cellular response, therapeutic drug monitoring, immunogenicity, quantitative systems pharmacology, inflammatory rheumatic diseases
Activités / CV
Clinical studies:
- Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA) NCT00497614 (Principal Investigator)
- Pharmaco Kinetic Variability of Infliximab in Rheumatoid Arthritis (FAKIR) NCT00840957 (Principal Investigator)
- Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA) NCT01382160 (Principal Investigator)
- Combinaison of Methotrexate to Adalimumab to Reduce Immunization in ankylosing Spondylitis (CoMARIS) NCT01895764 (Co-Investigator)
- Relationship between T LYmphocytes depletion and clinical response to RITUXimab in rheumatoid arthritis (LYRITUX) NCT02304354 (Co-Investigator)
- Effect of a new BI-specific antibody towards dendritic Cells on inflammation in Rheumatoid Arthritis (BIC-RA) NCT03416543 (Principal Investigator)
Informations complémentaires
Center for Molecular Biophysics, CNRS - Orleans
MabImprove Laboratory of Excellence
ENOTTA COST Action CA21147
Ten most significant publications during the last four years (2019-2022)
1. Bensalem A. et al., Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. Clin Pharmacokinet 59, 519-530 (2020).
3. Bitoun S. et al., Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies. JAMA Netw Open 6, e2323098 (2023).
4. Ducourau D. et al., Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. RMD Open 6, (2020).
5. Krieckaert C. L. et al., EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 82, 65-73 (2023).
6. Law-Wan J. et al. Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials. RMD Open 7, (2021).
7. van der Togt C. J. T. et al., Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD Open 9, (2023).
8. Skrede S, Bogavac-Stanojević N, Dreesen E, Nielsen E, Zaninotto M, Mulleman D. Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: A snapshot of laboratories and applications across Europe. Basic Clin Pharmacol Toxicol. 2024 Apr;134(4):556-560.
9. Moulin D et al. Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis. Ann Rheum Dis. 2024 Feb 15;83(3):312-323.
10. Lamendour L et al. Bispecific antibodies tethering innate receptors induce human tolerant-dendritic cells and regulatory T cells. Front Immunol. 2024 Mar 26;15:1369117.